{"entity":{"id":"nct06008106","kind":"trial","name":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma","aka":[],"tldr":"A phase 3 trial of Tunlametinib run by Shanghai Kechow Pharma, Inc. in melanoma, now recruiting.","summary":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma is a phase 3 interventional study registered as NCT06008106 by Shanghai Kechow Pharma, Inc., with 165 participants planned, started 2023-11-02. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06008106","url":"https://clinicaltrials.gov/study/NCT06008106"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","advanced-melanoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["tunlametinib"],"companies":["shanghai-kechow-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06008106","phase":"3","setting":"Efficacy and Safety of Tunlametinib Capsules Versus Combination Chemotherapy of Investigator's Choice in Advanced NRAS-mutant Melanoma Patients Who Had Previously Received Immunotherapy","sponsor":"Shanghai Kechow Pharma, Inc.","participation":[{"nct":"NCT06008106","source":"https://clinicaltrials.gov/study/NCT06008106","fetchedAt":"2026-10-07T16:54:05.353Z","studySha256":"3874e46f079035e2d91415ac70f04867c137d66fcfdb9fbdc2e746d62cdd99c1","overallStatus":"RECRUITING","lastUpdatePosted":"2024-06-28","leadSponsor":"Shanghai Kechow Pharma, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":165,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2023-11-02","startedType":"actual","enrolled":165,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06008106/","neighbours":{"cancer":[{"id":"acral-melanoma","kind":"cancer","name":"Acral melanoma","route":"/cancers/acral-melanoma/"},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","route":"/cancers/mucosal-melanoma/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"tunlametinib","kind":"drug","name":"Tunlametinib","route":"/drugs/tunlametinib/"}],"company":[{"id":"shanghai-kechow-pharma","kind":"company","name":"Shanghai Kechow Pharma","route":"/companies/shanghai-kechow-pharma/"}]}}